Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE – World's Largest Interventional Radiology

  Terumo to Showcase BSD's MicroThermX® Microwave Ablation System at CIRSE –
  World's Largest Interventional Radiology Conference

  *Over 6,000 medical professionals from 85 countries attend CIRSE
  *Terumo sponsoring focused training sessions for all Terumo sales
    representatives to capitalize on MicroThermX sales during the conference
  *Terumo is placing MicroThermX systems with key physician opinion leaders
    throughout Europe
  *Some of the world's leading experts in ablation will give presentations on
    MicroThermX

Business Wire

SALT LAKE CITY -- September 4, 2013

BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced
today that Terumo Europe NV (Terumo), a wholly owned subsidiary of Terumo
Corporation, will showcase BSD's MicroThermX^® Microwave Ablation System
(MicroThermX) at the annual Cardiovascular and Interventional Radiological
Society of Europe (CIRSE) conference. CIRSE, which will be held in Barcelona,
Spain, on September 14-18, 2013, is the world's largest and most prestigious
conference in the field of minimally invasive image-guided therapies. In
preparation for CIRSE, Terumo is sponsoring focused training sessions for all
Terumo sales representatives to ensure they are prepared to capitalize on
MicroThermX sales during the conference. As part of the overall sales strategy
for the conference, Terumo is placing MicroThermX systems with key physician
opinion leaders throughout Europe. Terumo will also send MicroThermX
promotional material to all conference attendees. Over 6,000 medical
professionals from 85 countries attend CIRSE, reflecting the global impact of
the rapidly expanding field of interventional radiology.

Terumo is also sponsoring a symposium at CIRSE highlighting the advantages of
the MicroThermX. The symposium will feature three presentations focused solely
on MicroThermX. "Microwave for lung tumour ablation: potential advantages
compared with radiofrequency ablation and clinical settings" will be presented
by Professor Philippe Pereira. "Microwave for liver tumour ablation: potential
advantages compared with radiofrequency ablation and clinical settings" will
be presented by Dr. Laura Crocetti. "Lessons from Microwave ablation with
MicroThermX™: why, when, where and how" will be presented by Dr. Damian Dupuy.
Professor Pereira and Drs. Crocetti and Dupuy are leading experts in the field
of interventional oncology.

"We are excited to announce that Terumo will focus on the MicroThermX at
CIRSE, the largest interventional oncology conference in the world. Terumo's
aggressive marketing strategy should allow them to capture a significant share
of the rapidly growing interventional oncology market," said Harold Wolcott,
BSD President and CEO. "BSD’s exclusive distribution agreement with Terumo
Europe NV for 100 countries represents one of the most significant milestones
in our corporate history. The potential market size for thermal ablation in
these countries is estimated to be in excess of $1 billion in annual sales."

About Terumo Corporation

A world leader in state-of-the-art medical devices and interventional
oncology, Tokyo-based Terumo Corporation (TYO: JP:4543) reported 2013 sales of
nearly $5 billion and has a market cap in excess of $8 billion. Through the
sale and promotion of a high quality line of devices used for tumor
embolization, the closing or blocking of blood vessels, Terumo Europe NV has
established itself as a pioneer in the field of interventional oncology.

About the MicroThermX^® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX is the first of its kind that allows delivery of higher power
levels using a single generator. The MicroThermX utilizes innovative
synchronous phased array technology that was developed and patented by BSD to
provide a wide range of uniform zones of ablation. The MicroThermX includes
innovative, high-end disposables (SynchroWave antennas) that are used in each
ablation treatment and will provide a significant ongoing revenue stream. The
soft tissue (tumor) ablation world market potential is estimated to exceed
$2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX for ablation of soft
tissue. BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX in Europe. CE Marking is also recognized
in many countries outside of the EU, providing BSD the ability to market the
MicroThermX to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.